Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Joe Healey’s Healthcor Bets on Celldex $CLDX

The last time we reported on Healthcor, they initiated an activist position in CareView Communications. Last week Healthcor disclosed a 5.86% stake in Celldex (CLDX) in a 13G filing. They paid around $3.30 per share on May 18th when the stock closed at $3.31. The stock currently trades at $3.70, giving Healthcor a 10+% return in less than two weeks.

Celldex Therapeutics, Inc. (NASDAQ:CLDX)

HealthCor Management is a $3 billion healthcare hedge fund founded by Arthur Cohen and Joseph Healey. Cohen graduated from the University of Virginia in 1983 with a B.A. degree in Commerce and received his M.B.A. in Banking and Finance from Hofstra University in 1986. He worked for Julian Robertson between 1995 and 2000. He was responsible for healthcare investments as a Managing Director at Tiger Management. He partnered with Joseph P. Healey in September 2005. The duo worked at Steven Cohen’s SAC until 2005.

Healey is a brilliant stock picker (See Joseph Healey’s stock recommendations at the 2009 Ira Sohn Conference). HealthCor returned 4% in 2008, vs. -19% for an average hedge fund. Cohen and Healey invest significant amounts in the healthcare industry by diversifying their portfolio in different stocks. Nearly two thirds of his investments are in the healthcare sector.

Celldex is a microcap stock and there aren’t a lot of hedge funds invested in this stock. D.E. Shaw had more than 1% of CLDX’s outstanding shares.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!